A comprehensive view of Branded Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

BIOGEN INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

U.S. Patent and Trademark Office Receives Regeneron Pharmaceuticals's Patent Application for Vegf Traps and Mini-Traps and Methods for Treating Ocular Disorders and Cancer

European Commission approves Jannsen's CARVYKTI ciltacabtagene autoleucel cilta-cel for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy; it is the first BCMA-targeted treatment approved by the EC

Patent Issued for Protein solution formulation containing high concentration of an anti-VEGF antibody (USPTO 11945859)

US Dept. of Justice files complaint alleging fraudulent drug pricing practices by Regeneron for its ophthalmology drug Eylea that cost Medicare hundreds of millions of dollars

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count